Ondine Biomedical Inc. Announces Collaboration to Advance Steriwave for ICU Market

Ondine Biomedical Inc. has announced a collaboration with the Royal Columbian Hospital (RCH) Foundation's Advancing Innovation in Medicine (AIM) division. This partnership focuses on the use of Steriwave® in intensive care units (ICUs) to prevent infections. A pilot study involving 320 patients will assess Steriwave's impact on infection prevention and patient outcomes, with potential expansion to a multicenter trial involving up to 2,000 patients. The C$855,000 study aims to integrate Steriwave into ICU protocols, potentially reducing infection rates and improving patient outcomes.

Dr. Steven Reynolds, leading the study, stated that Steriwave aims to eliminate nasal bacteria, reducing the risk of severe infections. Given the high rates of hospital-acquired infections (HAIs) in ICUs, this initiative could significantly reduce costs and patient suffering. The initial 25% tranche of the study's funding will involve issuing 950,000 new Common Shares at an Issue Price of C$0.225 per share. This effort reflects Ondine's commitment to revolutionizing infection control in ICUs globally.